Cargando…

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models

PURPOSE: Glioblastoma multiforme (GBM) is the most aggressive brain tumor. The activity of vosaroxin, a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, was investigated in GBM preclinical models as a single agent and combined with radiotherapy (RT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gravina, Giovanni Luca, Mancini, Andrea, Mattei, Claudia, Vitale, Flora, Marampon, Francesco, Colapietro, Alessandro, Rossi, Giulia, Ventura, Luca, Vetuschi, Antonella, Di Cesare, Ernesto, Fox, Judith A., Festuccia, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444710/
https://www.ncbi.nlm.nih.gov/pubmed/28415741
http://dx.doi.org/10.18632/oncotarget.16168
_version_ 1783238748711944192
author Gravina, Giovanni Luca
Mancini, Andrea
Mattei, Claudia
Vitale, Flora
Marampon, Francesco
Colapietro, Alessandro
Rossi, Giulia
Ventura, Luca
Vetuschi, Antonella
Di Cesare, Ernesto
Fox, Judith A.
Festuccia, Claudio
author_facet Gravina, Giovanni Luca
Mancini, Andrea
Mattei, Claudia
Vitale, Flora
Marampon, Francesco
Colapietro, Alessandro
Rossi, Giulia
Ventura, Luca
Vetuschi, Antonella
Di Cesare, Ernesto
Fox, Judith A.
Festuccia, Claudio
author_sort Gravina, Giovanni Luca
collection PubMed
description PURPOSE: Glioblastoma multiforme (GBM) is the most aggressive brain tumor. The activity of vosaroxin, a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, was investigated in GBM preclinical models as a single agent and combined with radiotherapy (RT). RESULTS: Vosaroxin showed antitumor activity in clonogenic survival assays, with IC(50) of 10−100 nM, and demonstrated radiosensitization. Combined treatments exhibited significantly higher γH2Ax levels compared with controls. In xenograft models, vosaroxin reduced tumor growth and showed enhanced activity with RT; vosaroxin/RT combined was more effective than temozolomide/RT. Vosaroxin/RT triggered rapid and massive cell death with characteristics of necrosis. A minor proportion of treated cells underwent caspase-dependent apoptosis, in agreement with in vitro results. Vosaroxin/RT inhibited RT-induced autophagy, increasing necrosis. This was associated with increased recruitment of granulocytes, monocytes, and undifferentiated bone marrow–derived lymphoid cells. Pharmacokinetic analyses revealed adequate blood-brain penetration of vosaroxin. Vosaroxin/RT increased disease-free survival (DFS) and overall survival (OS) significantly compared with RT, vosaroxin alone, temozolomide, and temozolomide/RT in the U251-luciferase orthotopic model. MATERIALS AND METHODS: Cellular, molecular, and antiproliferative effects of vosaroxin alone or combined with RT were evaluated in 13 GBM cell lines. Tumor growth delay was determined in U87MG, U251, and T98G xenograft mouse models. (DFS) and (OS) were assessed in orthotopic intrabrain models using luciferase-transfected U251 cells by bioluminescence and magnetic resonance imaging. CONCLUSIONS: Vosaroxin demonstrated significant activity in vitro and in vivo in GBM models, and showed additive/synergistic activity when combined with RT in O6-methylguanine methyltransferase-negative and -positive cell lines.
format Online
Article
Text
id pubmed-5444710
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-54447102017-06-01 Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models Gravina, Giovanni Luca Mancini, Andrea Mattei, Claudia Vitale, Flora Marampon, Francesco Colapietro, Alessandro Rossi, Giulia Ventura, Luca Vetuschi, Antonella Di Cesare, Ernesto Fox, Judith A. Festuccia, Claudio Oncotarget Research Paper PURPOSE: Glioblastoma multiforme (GBM) is the most aggressive brain tumor. The activity of vosaroxin, a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, was investigated in GBM preclinical models as a single agent and combined with radiotherapy (RT). RESULTS: Vosaroxin showed antitumor activity in clonogenic survival assays, with IC(50) of 10−100 nM, and demonstrated radiosensitization. Combined treatments exhibited significantly higher γH2Ax levels compared with controls. In xenograft models, vosaroxin reduced tumor growth and showed enhanced activity with RT; vosaroxin/RT combined was more effective than temozolomide/RT. Vosaroxin/RT triggered rapid and massive cell death with characteristics of necrosis. A minor proportion of treated cells underwent caspase-dependent apoptosis, in agreement with in vitro results. Vosaroxin/RT inhibited RT-induced autophagy, increasing necrosis. This was associated with increased recruitment of granulocytes, monocytes, and undifferentiated bone marrow–derived lymphoid cells. Pharmacokinetic analyses revealed adequate blood-brain penetration of vosaroxin. Vosaroxin/RT increased disease-free survival (DFS) and overall survival (OS) significantly compared with RT, vosaroxin alone, temozolomide, and temozolomide/RT in the U251-luciferase orthotopic model. MATERIALS AND METHODS: Cellular, molecular, and antiproliferative effects of vosaroxin alone or combined with RT were evaluated in 13 GBM cell lines. Tumor growth delay was determined in U87MG, U251, and T98G xenograft mouse models. (DFS) and (OS) were assessed in orthotopic intrabrain models using luciferase-transfected U251 cells by bioluminescence and magnetic resonance imaging. CONCLUSIONS: Vosaroxin demonstrated significant activity in vitro and in vivo in GBM models, and showed additive/synergistic activity when combined with RT in O6-methylguanine methyltransferase-negative and -positive cell lines. Impact Journals LLC 2017-03-13 /pmc/articles/PMC5444710/ /pubmed/28415741 http://dx.doi.org/10.18632/oncotarget.16168 Text en Copyright: © 2017 Gravina et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Gravina, Giovanni Luca
Mancini, Andrea
Mattei, Claudia
Vitale, Flora
Marampon, Francesco
Colapietro, Alessandro
Rossi, Giulia
Ventura, Luca
Vetuschi, Antonella
Di Cesare, Ernesto
Fox, Judith A.
Festuccia, Claudio
Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
title Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
title_full Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
title_fullStr Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
title_full_unstemmed Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
title_short Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
title_sort enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444710/
https://www.ncbi.nlm.nih.gov/pubmed/28415741
http://dx.doi.org/10.18632/oncotarget.16168
work_keys_str_mv AT gravinagiovanniluca enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT manciniandrea enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT matteiclaudia enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT vitaleflora enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT maramponfrancesco enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT colapietroalessandro enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT rossigiulia enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT venturaluca enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT vetuschiantonella enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT dicesareernesto enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT foxjuditha enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels
AT festucciaclaudio enhancementofradiosensitivitybythenovelanticancerquinolonederivativevosaroxininpreclinicalglioblastomamodels